Market Cap 2.77B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 30,970,602
Avg Vol 16,455,896
Day's Range N/A - N/A
Shares Out 446.50M
Stochastic %K 80%
Beta 0.71
Analysts Strong Sell
Price Target $7.95

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
djcal
djcal Aug. 8 at 8:16 PM
$IOVA I could write a book but going to leave it at I welcome all you chart people to sell it down to $3.90's - $4.33 range because the chart says so. I will be waiting to buy those shares.
1 · Reply
WebRub
WebRub Aug. 8 at 8:03 PM
$IOVA Doing DD doesn’t mean refusing to acknowledge a potential pullback. If $4.33 becomes old resistance/new support, that’s actually constructive for the larger setup. Nobody knows the exact path the market will take, so calling anyone “stupid and ignorant” for recognizing a possible retest isn’t DD , it’s just emotional conviction. Let the chart prove the thesis. If $4.33 holds and structure remains intact, I’ll be just as bullish on the next leg.
1 · Reply
dcbextreme
dcbextreme Aug. 8 at 7:56 PM
$IOVA What are your stock price predictions for the end of year? My guess is 8.50-9
4 · Reply
djcal
djcal Aug. 8 at 7:53 PM
$IOVA Anyone who sells this back down to $4.33 needs to have their head caved in with a bat lol. If anyone does that I will tell you now that you are both stupid and ignorant. You should be banned from bringing that stupidity and ingnorance into the market. Anyone thinking that has not done their DD. Serious. These people should only be allowed to trade on the OTC if even that. Maybe Monopoly where they use pretend money lol. Wow.
4 · Reply
djcal
djcal Aug. 8 at 7:37 PM
$IOVA Good point. I wish we could ask and get an answer from the FDA. Anyone know how to reach out to Fauci maybe he can get us a contact within the FDA pronto.
2 · Reply
nianga
nianga Aug. 8 at 6:40 PM
$IOVA In my view, the primary bottleneck for Replimune will be commercial adoption. By forcing the FDA's hand on a flawed BLA submission, management essentially compelled the agency to publicly spotlight the product's structural data weaknesses. Given how risk-averse clinicians and payors are, driving meaningful market penetration will be a significant uphill battle. While any clinical benefit for patients is a welcome outcome, Replimune's approval does not alter the core investment thesis for Iovance in the slightest.
3 · Reply
Merlintrader
Merlintrader Aug. 8 at 6:23 PM
$IOVA TIL cell therapy is now a commercial business: Q2 2026 revenue of roughly $99M, FY26 guidance of $350-370M and cash runway into 2028. IOV-5001 cleared by FDA for next-gen TIL. Closed 6.34 (+2.09%) on 31.0M shares. Educational content, not advice. https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
0 · Reply
Alibayli
Alibayli Aug. 8 at 6:20 PM
$IOVA Everything about IOVA is great, no argument there. But what really surprised me in a bad way was the FDA's approval of REPL. How does it work that FDA first called Replimune's claimed 34% ORR data inflated (basically accused them of manipulating the numbers), then turned around and accepted that same data as 24% ORR and granted accelerated approval anyway? Isn't that corruption? Won't other companies start suing the FDA over this tomorrow?$REPL
2 · Reply
Brad9s
Brad9s Aug. 8 at 6:12 PM
$IOVA Week 32: IOVA is up 55.8% this week and the market is up 4.0%
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 8 at 5:50 PM
1 · Reply
Latest News on IOVA
Iovance Biotherapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 2 days ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2026


Iovance Biotherapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 2 days ago

Iovance Biotherapeutics Earnings release: Q2 2026


Iovance Biotherapeutics Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 2 days ago

Iovance Biotherapeutics Quarterly report: Q2 2026


Iovance Biotherapeutics Slides: Corporate presentation

Jun 30, 2026, 7:00 AM EDT - 5 weeks ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics Transcript: AGM 2026

Jun 10, 2026, 11:00 AM EDT - 2 months ago

Iovance Biotherapeutics Transcript: AGM 2026


Iovance Biotherapeutics to Present at Upcoming Conference

May 21, 2026, 8:05 AM EDT - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conference


Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

2026-05-07T13:16:25.000Z - 3 months ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)


Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026


Iovance Biotherapeutics Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Earnings release: Q1 2026


Iovance Biotherapeutics Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Quarterly report: Q1 2026


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 5 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences


Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025


Iovance Biotherapeutics Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Annual report: Q4 2025


Iovance Biotherapeutics Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Earnings release: Q4 2025


Iovance Biotherapeutics Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 5 months ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 7 months ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025


Iovance Biotherapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Quarterly report: Q3 2025


Iovance Biotherapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Earnings release: Q3 2025


Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025


Iovance Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Quarterly report: Q2 2025


Iovance Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings release: Q2 2025


Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.


djcal
djcal Aug. 8 at 8:16 PM
$IOVA I could write a book but going to leave it at I welcome all you chart people to sell it down to $3.90's - $4.33 range because the chart says so. I will be waiting to buy those shares.
1 · Reply
WebRub
WebRub Aug. 8 at 8:03 PM
$IOVA Doing DD doesn’t mean refusing to acknowledge a potential pullback. If $4.33 becomes old resistance/new support, that’s actually constructive for the larger setup. Nobody knows the exact path the market will take, so calling anyone “stupid and ignorant” for recognizing a possible retest isn’t DD , it’s just emotional conviction. Let the chart prove the thesis. If $4.33 holds and structure remains intact, I’ll be just as bullish on the next leg.
1 · Reply
dcbextreme
dcbextreme Aug. 8 at 7:56 PM
$IOVA What are your stock price predictions for the end of year? My guess is 8.50-9
4 · Reply
djcal
djcal Aug. 8 at 7:53 PM
$IOVA Anyone who sells this back down to $4.33 needs to have their head caved in with a bat lol. If anyone does that I will tell you now that you are both stupid and ignorant. You should be banned from bringing that stupidity and ingnorance into the market. Anyone thinking that has not done their DD. Serious. These people should only be allowed to trade on the OTC if even that. Maybe Monopoly where they use pretend money lol. Wow.
4 · Reply
djcal
djcal Aug. 8 at 7:37 PM
$IOVA Good point. I wish we could ask and get an answer from the FDA. Anyone know how to reach out to Fauci maybe he can get us a contact within the FDA pronto.
2 · Reply
nianga
nianga Aug. 8 at 6:40 PM
$IOVA In my view, the primary bottleneck for Replimune will be commercial adoption. By forcing the FDA's hand on a flawed BLA submission, management essentially compelled the agency to publicly spotlight the product's structural data weaknesses. Given how risk-averse clinicians and payors are, driving meaningful market penetration will be a significant uphill battle. While any clinical benefit for patients is a welcome outcome, Replimune's approval does not alter the core investment thesis for Iovance in the slightest.
3 · Reply
Merlintrader
Merlintrader Aug. 8 at 6:23 PM
$IOVA TIL cell therapy is now a commercial business: Q2 2026 revenue of roughly $99M, FY26 guidance of $350-370M and cash runway into 2028. IOV-5001 cleared by FDA for next-gen TIL. Closed 6.34 (+2.09%) on 31.0M shares. Educational content, not advice. https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
0 · Reply
Alibayli
Alibayli Aug. 8 at 6:20 PM
$IOVA Everything about IOVA is great, no argument there. But what really surprised me in a bad way was the FDA's approval of REPL. How does it work that FDA first called Replimune's claimed 34% ORR data inflated (basically accused them of manipulating the numbers), then turned around and accepted that same data as 24% ORR and granted accelerated approval anyway? Isn't that corruption? Won't other companies start suing the FDA over this tomorrow?$REPL
2 · Reply
Brad9s
Brad9s Aug. 8 at 6:12 PM
$IOVA Week 32: IOVA is up 55.8% this week and the market is up 4.0%
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 8 at 5:50 PM
1 · Reply
Fire_Truck
Fire_Truck Aug. 8 at 5:49 PM
$IOVA Just posting this for those that don't know or forgot about.
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Aug. 8 at 5:49 PM
0 · Reply
drose0527
drose0527 Aug. 8 at 5:48 PM
$IOVA where IOVA currently sits into structure and market symmetry we will likely peak at or near 9 in the incoming 2 weeks. We will have completed 5 full impulses to complete leg 1 of Elliot wave sequence. Which is 1/3 of our total move. So 9 if we get there we can see 25-27 in 2 years time. Now we will sell off. At 9 and when we do big money will come in. On this sell off cause they will be the fuel for us going to 18 over the next year as our current business cycle is shifting to our wheel house. As recession stocks will take center stage in our economy by November. So I see our path over the next year going like this. Sell off back to 4.33 old resistance new support. It fits the place where big money gets a 4:1 return on their investment. So 4.31x4=17.24 or 18 which is all based on our next cycle peaks. So 4.33 to 10 for our cup completion. Just like we did. From 10-6. As big money wants to compound gains! 6-15 as wave 3 can run on average 1.5 times wave 1. 15-12 12 to 17-18.
4 · Reply
dogbone98
dogbone98 Aug. 8 at 5:34 PM
$IOVA It will be interesting to see what follows the REPL capitulation by the FDA. Was the decision a "one-off" to be able to move on from a political & PR mess, or does it signal a sea-change at the FDA, where the FDA will place more weight on getting promising therapies into the market, than on adhering to high trial & data standards? If the latter, then there's no reason TILVANCE and LUN shouldn't get immediate approval. Especially since those trials and the data are cleaner than what REPL offered.
1 · Reply
Brad9s
Brad9s Aug. 8 at 5:02 PM
$IOVA 46,26,26,14. Dilution last 4 quarters. I like that trend
3 · Reply
BioCrazy1
BioCrazy1 Aug. 8 at 4:26 PM
$IOVA Hurry up Big Pharma. Big Pharma does not like buying companies after they have already scaled manufacturing, proven commercial execution across multiple solid tumors, and locked in next generation improvements. At that stage the valuation is higher, the integration risk is different, and the target has more leverage (or may simply prefer to remain independent). Given Iovances Clear public stance against dilutive partnerships Largest shareholder with a track record of building and selling Expanding clinical and commercial momentum the window for a clean strategic acquisition is open but not indefinite. The more successful the frontline melanoma data, the lung program, and the additional indications become, the more expensive (and politically harder) the deal gets. The pipeline depth turns a solid oncology asset into a must own platform. Merck and BMS control the primary frontline standards for solid tumors. Do they want to control 2nd line which IOVA will dominate?
6 · Reply
Fire_Truck
Fire_Truck Aug. 8 at 4:20 PM
$IOVA So it looks like they did dilute a little over 6M shares from the Q1 to Q2 Almost 453 million outstanding shares now.
5 · Reply
Badgerkid
Badgerkid Aug. 8 at 3:49 PM
$IOVA I was away on a business trip, what did I miss?😃 I'm finally getting the chance to listen to the call, catch up on messages, and review all the numbers. I hope I'm not the first person to say it, but it sure looks like "remarkable growth" to me. Remember all those people who slammed that statement? When a CFO of Corleen Roche's stature uses that expression, as I said previously, it usually infers better than a 30-35% rate of growth. Looks like we got all of that and then some. Apparently, it also means a revenue surge, healthier margins, stronger cash flow, market expansion, product expansion, a much longer cash runway, and any number of other things which I'm sure many of you heard in the call. It would seem that my reasons to remain long and add shares to my positions were duly justified. I remain long for all that's ahead. GL to all IOVA investors and blessings for all those cancer patients who will be given new reasons to hope for better treatments and potential cures.
3 · Reply
Comicguy
Comicguy Aug. 8 at 3:49 PM
$REPL $IOVA If any of this were true both whould be in big trouble with SEC so we know you are full of it.
3 · Reply
bullishonHRTX
bullishonHRTX Aug. 8 at 3:47 PM
$IOVA the FDA staff's opinion on$REPL RP1 will continue to stick with its credibility. I will just stay with $IOVA. good that melanoma patients have options, but I bet many will go with the IOVA better option with a better outcome guarantee
1 · Reply
JenniferSharp981
JenniferSharp981 Aug. 8 at 3:39 PM
$ZS $IOVA $VRTX $MSTX $ZTS Zscaler remains a leader in cloud cybersecurity, Iovance focuses on commercializing cell therapy, Vertex continues expanding its biotechnology portfolio, MSTX provides leveraged exposure to MicroStrategy, and Zoetis benefits from resilient animal-health demand. I'm watching recurring revenue, clinical execution, and Bitcoin exposure.
0 · Reply
marc1991
marc1991 Aug. 8 at 3:19 PM
$IOVA something heard about a new CMO in ER?
1 · Reply